Magnus Polla
AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Synthetic Organic Chemistry Methods, Receptor Mechanisms and Signaling, Peptidase Inhibition and Analysis, Computational Drug Discovery Methods, Chemical Synthesis and Analysis
Most-Cited Works
- → Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway(2019)291 cited
- → Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)(2004)57 cited
- → The acute glucose lowering effect of specific GPR120 activation in mice is mainly driven by glucagon-like peptide 1(2017)51 cited
- → Synthesis of optically active cyclohexenol derivatives via enzyme catalyzed ester hydrolysis of 4-acetoxy-3-methyl-2-cyclohexenone(1991)44 cited
- → Discovery of AZD8165 – a clinical candidate from a novel series of neutral thrombin inhibitors(2015)25 cited
- → The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays(2006)23 cited
- → New synthesis of a taxol A-ring system.(1993)15 cited
- → Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa)(2014)14 cited
- → Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: Development of highly selective CPU substrates as useful tools for assay development(2007)12 cited
- → Toward Second‐Generation Cardiomyogenic and Anti‐cardiofibrotic 1,4‐Dihydropyridine‐Class TGFβ Inhibitors(2019)10 cited